Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study
Key facts
- Who runs it
- Bio Refine Ltd.
- Where
- Hungary, Israel, Poland, and Serbia8 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 3 Jun 2024
- Expected to end
- Apr 2028
- Type of study
- Interventional
- Treatments tested
- Coriofix System
- Record updated
- 2 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Local heart team has determined that mitral valve surgery will not be offered as a treatment option
- Symptomatic secondary mitral regurgitation (3+ or 4+)
- Adequately treated in compliance with optimal guideline-directed medical therapy for heart failure for at least 90 days
- NYHA functional class II, III or ambulatory IV
- LVEF ≥30%
- Written informed consent has been obtained
Who cannot take part
- CABG, PCI or TAVR within the prior 90 days
- COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use
- CVA or TIA within prior 180 days
- Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
- Currently participating in an investigational drug or another device study that has not reached its primary endpoint
- Untreated clinically significant coronary artery disease requiring revascularization
- Aortic or tricuspid valve disease requiring surgery or transcatheter intervention or severe tricuspid regurgitation
- Any history of ventricular arrythmia
- Life expectancy <12 months due to non-cardiac conditions
- Hypotension
- Patients implanted with any kind of CIED
- TEE is contraindicated or high risk
- Pregnant or planning pregnancy within next 12 months
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and feasibility of the Bio Refine Coriofix System and determine if it might help in treatment of functional mitral regurgitation.
Read full original descriptionShow less
The study will include patients with symptomatic secondary mitral regurgitation in whom mitral surgery cannot and/or will not be offered as a treatment option (the risk is prohibitive).
Potential patients will be screened to confirm that all inclusion/exclusion criteria are met, with final eligibility confirmation on day of procedure.
All enrolled subjects who went through the procedure will be followed during the procedure to hospital discharge.
Additional follow up time points are scheduled at 30 days, 6 months and 12 months post procedure.
The group in the trial
- Coriofix treatmentTreatment being tested
Treatment: Coriofix System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 2 October 2026